2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

tality from gynecologic cancers are increasing in Europe,
and all women—especially older women—are at risk. Trustworthy
public and patient information and education are
lacking, especially in non–English–speaking countries.
As the leading European professional society related to
cancer, ESGO shares the goal of patient groups to help
women living with gynecologic cancers to obtain accurate,
reliable, and timely information about their disease, to
understand treatment options and to have access to the best
possible care. For the first time, during ESCO 17 the Society
organized a seminar for European patient groups with an
interest in gynecologic cancers. Fifty participants, including
38 representatives of patient organizations, attended.
ESGO shares common goals with patient organizations,
and wishes to become a real facilitator of different patientrelated
activities across Europe. The seminar at ESGO 17
was only the start of the partnership, and ESGO is committed
to provide a continuing platform for patient organizations
to meet and work together. Ten recommendations
coming out of this patient seminar have been approved by
the ESGO Council, and a small committee formed to take
these forward in 2012.
Focus on the Younger Generation: ENYGO
ENYGO is a network for young professionals and trainees
in gynecologic oncology and related subspecialties. ENYGO
was created in 2009 and is supported in its activities by
ESGO. ENYGO is the principal European network representing
the needs and aspirations of all trainees involved in
the study, prevention, and treatment of gynecological cancers.
It serves as a forum for promoting scientific and social
interaction, discussion, debate, and exchange of ideas and
views among trainees. ENYGO currently has approximately
400 members from 40 countries across Europe, with each
country having a national representative. ENYGO is represented
on the ESGO council by its president and supported
by a vice president and an executive group.
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
ENYGO Activities at ESGO 17
ENYGO had its own session during the 17th ESGO
conference. Details of outcomes from this workshop include:
1) an introduction and retrospection about ENYGO by
Dr. Michaela Bossart and past-president Dr. Boris Vranes;
2) presentation of the initial results of the first Europe-wide
survey on training experiences of European gynecologic
oncology trainees by Dr. Ranjit Manchanda, which clearly
highlighted the differences in training across countries and
the importance and need for accredited training for trainees;
3) an update on Teaching the Teachers workshop presented
by Dr. Jurgen Piek, which highlighted the importance of
training teaching according to modern concepts and mechanisms
such as the CanMEDS framework and specific, measurable,
attainable, rewarding, time-bound (SMART) rules
to facilitate the phenomenon of lifelong learning; 4) a presentation
on training systems in Europe by Dr. Murat
Gultekin; and 5) the launch and hard-copy/CD-ROM distribution
of the second edition of the Textbook of Gynaecological
Oncology, which was a big success and greatly appreciated
by all trainees.
Subsequently, Dr. Ranjit Manchanda coordinated an Internet
survey, to which 154 members responded. This
showed that surgical anatomy and laparoscopic surgery in
gynecologic oncology were the topics most members would
like to see covered by workshops. On the basis of these
results, ENYGO is facilitating the organization of a combined
2-day workshop focusing on surgical anatomy and
laparoscopic surgery in London in September 2012. After
the successful Teaching the Teachers (TTT) workshop in
Amsterdam, the Netherlands, in May 2011, the next TTT
workshop is proposed to be held in Macedonia in June 2012.
ENYGO will also help facilitate and organize a young
gynecologic oncologist session (YDS—Young Doctors’ Session)
at the upcoming IGCS conference in Vancouver,
Canada.
Stock
Ownership Honoraria
Research
Funding
Renata Brantnerova*
Ranjit Manchanda Abbott
Laboratories
Nicoletta Colombo Cancer
Research UK;
The Eve Appeal
*No relevant relationships to disclose.
1. International Agency for Research on Cancer. Globocan 2008 Fast Stats
Factsheet: Europe. http://globocan.iarc.fr/factsheet.asp. Accessed February
24, 2012.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence
and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-781.
3. Arbyn M, Raifu AO, Autier P, et al. Burden of cervical cancer in Europe:
estimates for 2004. Ann Oncol. 2007;18:1708-1715.
4. Ledermann J, Harter P, Gourley C, et al. Phase 2randomized placebocontrolled
study of olaparib(AZD2281) in patients with platinum-sensitive
relapsed serous ovarian cancer (PSR SOC) Int J Gynecol Cancer. 2011;21:S13.
5. Del Conte G, Sessa C, von Moos R, et al. Antitumor activity of olaparib
(AZD2281) and liposomal doxorubicin in previously treated ovarian cancer
patients. Int J Gynecol Cancer. 2011;21:S20.
338
REFERENCES
BRANTNEROVA, MANCHANDA, AND COLOMBO
Expert
Testimony
Other
Remuneration
6. Fischerova D, Freitag P, Zikan M, et al. The role of ultrasound in
planning fertility sparing surgery and individual treatment in early stage
cervical cancer. Int J Gynecol Cancer. 2011;21:S107.
7. Lai D, Wang F, Chen Y at al. Human ovarian cancer stem cells can be
efficiently killed by gamma dekta T-lymphocytes. Int J Gynecol Cancer.
2011;21:S45.
8. Tian WJ, Chi DS, Sehouli J, et al. A risk Model for secondary cytoreductive
surgery in recurrent ovarian cancer: an evidence-based proposal for
patient selection. Int J Gynecol Cancer. 2011;21:S55.
9. Vergote I, Pujade-Lauraine E, Pignata S, et al. European Network of
Gynaecological Oncological Trial Groups’ requirements for trials between
academic groups and pharmaceutical companies. Int J Gynecol Cancer.
2010;20:476-478.